Natera Showcases Expansive Oncology Research Program at ASCO 2026, Highlighting Advances in MRD Testing and Precision Cancer Care
Natera announced an extensive oncology research program for the 2026 Annual Meeting of the American Society of Clinical Oncology, underscoring the company’s growing influence in molecular residual disease (MRD) testing and precision oncology. The conference, scheduled to take place from May 29 through June 2 in Chicago, Illinois, will feature 35 abstracts involving Natera and its collaborators, marking the company’s largest oncology-focused scientific presentation effort to date.
The presentations will center on the expanding clinical applications of Signatera, Natera’s personalized circulating tumor DNA (ctDNA) assay, and the company’s evolving Treatment on MRD (TOMR) strategy. The data being presented span multiple cancer types and clinical settings, reflecting increasing interest in MRD-guided treatment decisions and the broader integration of ctDNA testing into routine oncology care.
According to the company, the ASCO program is designed to demonstrate the broad clinical utility of Signatera in identifying molecular recurrence, monitoring treatment response, and enabling more personalized disease management strategies. The studies also emphasize the scalability of Natera’s evidence-generation efforts across both clinical trial and real-world settings.
Alexey Aleshin, M.D., corporate chief medical officer and general manager of oncology at Natera, described the ASCO 2026 data package as the company’s most comprehensive oncology presentation to date. He noted that the volume and diversity of the studies reflect increasing adoption of MRD-guided approaches in cancer treatment and the continued expansion of Signatera across multiple tumor types.
The company’s research program includes important findings from colorectal cancer studies, pan-cancer MRD analyses, evaluations of its ultra-sensitive phased variant technology, and the introduction of new digital tools intended to improve interpretation and contextualization of genomic information.
Expanding Evidence for MRD-Guided Treatment in Colorectal Cancer
A significant portion of Natera’s ASCO presentations focuses on colorectal cancer (CRC), particularly findings from the ongoing GALAXY study. The analyses presented from GALAXY explore how serial MRD testing with Signatera may help clinicians tailor adjuvant chemotherapy decisions more precisely after surgery.
One of the featured analyses examined outcomes among patients who initially tested negative for ctDNA following surgery but later converted to Signatera-positive status during surveillance. The findings indicated that these patients experienced substantial benefit from adjuvant chemotherapy, with a hazard ratio of 0.3. The data suggest that serial MRD monitoring can identify patients experiencing early molecular recurrence before conventional imaging or clinical symptoms emerge.
Researchers believe this type of molecular surveillance may help oncologists intervene earlier in the disease course, potentially improving outcomes by initiating therapy when tumor burden remains extremely low. The findings also support the broader TOMR framework, which emphasizes treatment decisions based on evolving MRD status rather than relying solely on traditional clinical indicators.
The GALAXY analyses also identified a group of patients who maintained sustained Signatera-negativity throughout monitoring. These patients demonstrated favorable outcomes regardless of whether they received adjuvant chemotherapy, suggesting that some individuals may be exposed to unnecessary treatment and associated toxicities despite having a low risk of recurrence.
Another analysis from the study evaluated the optimal duration of adjuvant chemotherapy in relation to molecular response patterns. Investigators reported that extending chemotherapy beyond three months provided no additional benefit for patients who remained persistently Signatera-negative or achieved complete ctDNA clearance during treatment.
However, the results differed for patients who exhibited only partial molecular responses, defined as declining but still detectable ctDNA levels. These individuals appeared to benefit from prolonged chemotherapy treatment, indicating that ctDNA dynamics may help guide treatment duration decisions more effectively.
Conversely, patients whose ctDNA levels increased during therapy — categorized as molecular progression — demonstrated poor outcomes despite ongoing treatment. These findings suggest that standard chemotherapy may be insufficient for this subgroup and that alternative therapeutic strategies could be necessary.
Together, the colorectal cancer analyses reinforce the growing role of MRD testing in refining adjuvant treatment decisions and advancing more individualized cancer management approaches.
Pan-Cancer Meta-Analysis Demonstrates Broad Clinical Utility of Signatera
Beyond colorectal cancer, Natera will also present one of the largest real-world meta-analyses conducted to date involving MRD testing across multiple tumor types.
The pooled analysis incorporated data from 18 published studies involving more than 3,000 patients across 15 different cancers. According to the company, the study evaluated the relationship between Signatera positivity and clinical outcomes at multiple stages of disease monitoring.
The findings demonstrated that Signatera positivity consistently correlated with significantly increased risks of recurrence or disease progression across all evaluated timepoints.
In the adjuvant treatment window, patients who tested positive for Signatera showed a markedly increased likelihood of recurrence or death, with a hazard ratio of 8.15 compared to MRD-negative patients.
The association became even stronger during surveillance monitoring after completion of therapy. In this setting, Signatera-positive patients experienced a hazard ratio of 18.30 for recurrence risk, highlighting the strong prognostic significance of detectable ctDNA during long-term follow-up.
The meta-analysis is expected to strengthen the argument for broader integration of MRD testing into clinical oncology workflows. By aggregating evidence across numerous studies and tumor types, the research supports the concept that ctDNA detection can function as a pan-cancer biomarker for recurrence risk assessment and disease monitoring.
The company believes these data reinforce Signatera’s position as a foundational tool in precision oncology and support its use across increasingly diverse cancer settings.
Phased Variant Technology Demonstrates Ultra-Sensitive Detection Capabilities
Another major focus of Natera’s ASCO 2026 program is the company’s phased variant technology platform, which is designed to achieve extremely high sensitivity in ctDNA detection.
The technology can reportedly detect ctDNA levels below one part per 10 million, enabling identification of minimal residual disease at exceptionally low concentrations. Natera and its collaborators presented data showing how this enhanced sensitivity may improve prognostic accuracy and long-term disease monitoring across both solid tumors and hematologic malignancies.
One study involving patients with early-stage non-small cell lung cancer (NSCLC) produced particularly notable findings. Investigators reported that all patients who achieved ctDNA clearance during or after adjuvant therapy remained recurrence-free throughout follow-up.
The study also showed that ctDNA detection preceded clinical recurrence in 94% of cases, suggesting that ultra-sensitive MRD testing may provide substantial lead time before disease becomes detectable through imaging or other conventional methods.
These findings underscore the potential value of ctDNA monitoring in assessing treatment effectiveness and identifying recurrence earlier than traditional surveillance approaches.
Natera also highlighted data from patients with relapsed or refractory follicular lymphoma treated with CAR T-cell therapy. In this analysis, patients who achieved MRD negativity following treatment experienced significantly improved progression-free survival outcomes.
The 36-month progression-free survival rate reached 81% among MRD-negative patients, compared to 56% in individuals who remained MRD-positive after therapy. The results suggest that MRD status may serve as an important biomarker for evaluating long-term treatment success in hematologic cancers.
The studies collectively demonstrate how ultra-sensitive ctDNA detection technologies may help clinicians make more informed decisions regarding treatment response, relapse risk, and disease management over extended periods.
Real-World Data and Digital Platform Expansion
In addition to clinical trial findings, Natera’s ASCO presentations will feature multiple real-world data analyses evaluating ctDNA dynamics and patient outcomes across several tumor types, including colorectal cancer, breast cancer, and NSCLC.
These real-world studies are intended to complement clinical trial evidence by demonstrating how Signatera performs in routine clinical practice across diverse patient populations and treatment settings.
The company also plans to introduce a new digital platform called Annotation during the conference. The tool is designed to integrate genomic information with clinical and treatment data to create comprehensive longitudinal patient profiles.
According to Natera, the Annotation platform enables clinicians and researchers to visualize multimodal patient journeys through a unified interface, providing richer context around Signatera results at both individual and cohort levels.
The platform is expected to support more advanced interpretation of MRD trends over time while helping clinicians correlate ctDNA findings with treatment history, imaging, and broader clinical outcomes.
As precision oncology continues to evolve, digital platforms that combine molecular and clinical information are becoming increasingly important for translating complex genomic data into actionable treatment insights.
Growing Momentum for Precision Oncology
Natera’s extensive ASCO 2026 presence reflects the broader momentum behind MRD-guided cancer care and the increasing role of liquid biopsy technologies in oncology.
The company’s 35-study program spans a wide range of clinical applications, from recurrence prediction and therapy selection to long-term surveillance and treatment response assessment. The breadth of the research also highlights growing collaboration between academic institutions, clinical investigators, and biotechnology companies focused on advancing personalized cancer treatment strategies.
As oncologists continue seeking more precise ways to identify relapse risk and optimize therapy decisions, MRD testing technologies such as Signatera are becoming increasingly central to discussions surrounding the future of cancer management.
The findings being presented at ASCO 2026 may further strengthen the clinical evidence supporting ctDNA-guided care and contribute to broader adoption of precision oncology approaches across multiple cancer types.
About Natera
Natera™ is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives.
Natera’s tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado.
